Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
January 1 - September 30, 2024
- Net sales were TSEK 8,408 (7,248), +16%.
- The loss after tax was TSEK 17,753 (12,786).
- The loss per share was SEK 0.08 (0.11).
- The cash flow from current operations was negative in the amount of TSEK 16,745 (17,827).
- The gross margin was 75.7% (68.2%).
- Electrode sales volume increased by 2% and was 17,210 (16,922) units. Repeat sales of electrodes to existing customers decreased by 7% as Q3-23 included large electrode orders prior to a price increase.
- Net sales were TSEK 21,107 (17,481), +21%.
- The loss after tax was TSEK 43,663 (35,044).
- The loss per share was SEK 0.27 (0.34).
- The cash flow from current operations was negative in the amount of TSEK 44,835 (34,633).
- The gross margin was 72.0% (67.5%).
- Electrode sales volume increased by 13% and was 45,078 (39,866) units. Repeat sales of electrodes to existing customers increased by 10%.
- Overall sales increased by 16% (+17, before currency effects). Sales in Germany within the skin cancer segment decreased by 8% (6% in local currency) following some customers building up inventory in Q3-23. Sales in the US skin cancer market increased by 187% while the sales within the skin barrier segment increased by 102%.
In the US a Consensus report by leading US clinicians assessing technologies for melanoma detection and management was published. The report concluded that the Nevisense AI-driven technology can significantly enhance early melanoma detection.
The National Institutes of Health (NIH), one of the world's foremost medical research centers and a part of the U.S. Department of Health and Human Services, purchased Nevisense for research on the skin barrier. This sale represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research in this area.
SciBase continued to expand in the US with new customers in new regions.
SciBase announced the change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).
A Nomination Committee has been appointed for SciBase Holding's Annual General Meeting in 2025.
SciBase initiates sales collaboration in Italy.
SciBase decides on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million.
Oct 1,
2023 -
July Jan 1 Sep 30, Jan 1 - Dec 31
1 - - Sep 2024
Sep 30
30
THE GROUP 2024 2023 2024 2023 Rolling 2023
-12
Net sales, SEK ths 8 408 7 248 21 17 26 870 23 245
107 481
Gross margin, % 75,7% 68,2% 72,0% 67,5% 72,3% 69,0%
Equity/Asset ratio, % 67,6% 72,4% 67,6% 72,4% 70,4% 66,9%
Net indebtness, multiple 0,48 0,38 0,48 0,38 0,42 0,49
Cash equivalents, SEK ths 24 52 24 52 24 714 34 121
714 353 714 353
Cashflow from operating -16 -17 -44 -34 -62 187 -51 984
activities, SEK ths 475 827 835 633
Earnings per share -0,08 -0,11 -0,27 -0,34 -0,42 -0,51
(before and after
dilution), SEK
Shareholder's equity per 0,17 0,50 0,23 0,58 0,32 0,40
share, SEK
Average number of shares, 219 119 164 104 153 067 107 980
000' 538 831 146 029
Number of shares at 219 119 219 119 219 538 119 831
closing of period, 000'* 538 831 538 831
Share price at end of 0,48 1,24 0,51 1,24 0,51 0,83
period, SEK
Number of sold 17 16 45 39 57 132 51 920
electrodes, pieces 210 922 078 866
Average number of 29 23 27 22 27 23
employees
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 12, 2024.
This report has been comprehensively reviewed by the Company's auditors.
For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: certifiedadviser@carnegie.se
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.